Yeah, I think that one of the things that patients are certainly very interested in beyond just prolonging their survival or prolonging their time until their disease recurs is the concept of cures. I think that we are definitely reaching a point in solid tumor oncology and kidney cancer in particular, whereby we can start thinking in terms of how do we maximize the odds of actually curing patients, eradicating their disease completely from their body, both in the earlier stages where it is more feasible, but even in the stage four metastatic stage, I think we can start seriously considering how we can optimize the therapies to include the cure fraction beyond just prolonging survival times...
Yeah, I think that one of the things that patients are certainly very interested in beyond just prolonging their survival or prolonging their time until their disease recurs is the concept of cures. I think that we are definitely reaching a point in solid tumor oncology and kidney cancer in particular, whereby we can start thinking in terms of how do we maximize the odds of actually curing patients, eradicating their disease completely from their body, both in the earlier stages where it is more feasible, but even in the stage four metastatic stage, I think we can start seriously considering how we can optimize the therapies to include the cure fraction beyond just prolonging survival times. And there are very good modeling strategies that have been developed in the past two decades in the statistical design space that can help us actually do these types of analyses with already existing clinical data and incorporate them in novel clinical trial designs.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
